FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2167325977> ?p ?o ?g. }

• W2167325977 endingPage "e193" @default.
• W2167325977 startingPage "e186" @default.
• W2167325977 abstract "Tyrosine-kinase inhibitors improve overall survival in patients with chronic myeloid leukaemia in chronic phase (CML-CP). Survival compared with the general population by age, response, and type of tyrosine-kinase inhibitor is not known. With use of data from trials of tyrosine kinase inhibitors, we compared overall survival in patients with newly diagnosed CML-CP to that of general population.In this cohort analysis, we included data from patients with CML-CP enrolled in six consecutive or parallel prospective clinical trials of tyrosine-kinase inhibitors at a single institution from July 30, 2000, to Sept 17, 2012. We analysed data for response and survival with the Kaplan-Meier method. For estimated overall survival in the general population, we obtained data from national vital statistics reports and matched to patients with CML-CP by age, sex, ethnicity, and year at diagnosis. We assessed numbers and causes of death within 1 year of beginning treatment by age group and by response to therapy. We then did univariate analysis and multivariate analysis to investigate factors associated with survival probability.Our analysis included 483 patients, 271 received imatinib, 105 received nilotinib, and 107 received dasatinib. Most patients were younger than 65 years, and no patients were older than 85 years. Median follow-up was 99·4 months (IQR 44·9-121·6), by which time 53 (11%) patients had died. The most common causes of death were progression to advanced disease stage, including complications of stem-cell transplantation (17 [4%] patients), secondary malignancies (nine [2%] patients), and cardiovascular causes (nine [2%] patients). 5-year overall survival in patients with CML-CP decreased in older age categories. For the whole population of patients with CML-CP, 5-year survival was only slightly lower than that of the matched general population (relative survival 94·7% [95% 92·1-97·4]). Individuals of all ages with a report of complete cytogenetic response to treatment or deeper within 1 year had a 5-year survival similar to that of the general population.In the era of treatment with tyrosine-kinase inhibitors, patients diagnosed with CML-CP can expect a 5-year survival that is only slightly lower than that of the general population. With access to tyrosine-kinase inhibitors, most patients with chronic myeloid leukaemia could enjoy a near normal life expectancy.MD Anderson Cancer Center, National Cancer Institute." @default.
• W2167325977 created "2016-06-24" @default.
• W2167325977 creator A5000750846 @default.
• W2167325977 creator A5006104041 @default.
• W2167325977 creator A5013519008 @default.
• W2167325977 creator A5015140142 @default.
• W2167325977 creator A5022647201 @default.
• W2167325977 creator A5029750735 @default.
• W2167325977 creator A5036349678 @default.
• W2167325977 creator A5049385583 @default.
• W2167325977 creator A5055045706 @default.
• W2167325977 creator A5085419504 @default.
• W2167325977 creator A5088307376 @default.
• W2167325977 creator A5090435894 @default.
• W2167325977 date "2015-05-01" @default.
• W2167325977 modified "2023-10-12" @default.
• W2167325977 title "Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials" @default.
• W2167325977 cites W1514558457 @default.
• W2167325977 cites W1776669288 @default.
• W2167325977 cites W1965493606 @default.
• W2167325977 cites W1966006461 @default.
• W2167325977 cites W1968747503 @default.
• W2167325977 cites W1983815119 @default.
• W2167325977 cites W2001335864 @default.
• W2167325977 cites W2013428225 @default.
• W2167325977 cites W2018195863 @default.
• W2167325977 cites W2050086414 @default.
• W2167325977 cites W2057206328 @default.
• W2167325977 cites W2067428197 @default.
• W2167325977 cites W2068977368 @default.
• W2167325977 cites W2075193502 @default.
• W2167325977 cites W2085342571 @default.
• W2167325977 cites W2093487133 @default.
• W2167325977 cites W2104694028 @default.
• W2167325977 cites W2107268345 @default.
• W2167325977 cites W2135620625 @default.
• W2167325977 cites W2140974115 @default.
• W2167325977 cites W2146658081 @default.
• W2167325977 cites W2156145496 @default.
• W2167325977 cites W2157330275 @default.
• W2167325977 cites W2157436488 @default.
• W2167325977 cites W2159619867 @default.
• W2167325977 cites W2162760243 @default.
• W2167325977 cites W2168633862 @default.
• W2167325977 cites W2429298507 @default.
• W2167325977 cites W246272317 @default.
• W2167325977 cites W2979511046 @default.
• W2167325977 cites W1981357862 @default.
• W2167325977 cites W2405605510 @default.
• W2167325977 doi "https://doi.org/10.1016/s2352-3026(15)00048-4" @default.
• W2167325977 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4884053" @default.
• W2167325977 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26688093" @default.
• W2167325977 hasPublicationYear "2015" @default.
• W2167325977 type Work @default.
• W2167325977 sameAs 2167325977 @default.
• W2167325977 citedByCount "209" @default.
• W2167325977 countsByYear W21673259772015 @default.
• W2167325977 countsByYear W21673259772016 @default.
• W2167325977 countsByYear W21673259772017 @default.
• W2167325977 countsByYear W21673259772018 @default.
• W2167325977 countsByYear W21673259772019 @default.
• W2167325977 countsByYear W21673259772020 @default.
• W2167325977 countsByYear W21673259772021 @default.
• W2167325977 countsByYear W21673259772022 @default.
• W2167325977 countsByYear W21673259772023 @default.
• W2167325977 crossrefType "journal-article" @default.
• W2167325977 hasAuthorship W2167325977A5000750846 @default.
• W2167325977 hasAuthorship W2167325977A5006104041 @default.
• W2167325977 hasAuthorship W2167325977A5013519008 @default.
• W2167325977 hasAuthorship W2167325977A5015140142 @default.
• W2167325977 hasAuthorship W2167325977A5022647201 @default.
• W2167325977 hasAuthorship W2167325977A5029750735 @default.
• W2167325977 hasAuthorship W2167325977A5036349678 @default.
• W2167325977 hasAuthorship W2167325977A5049385583 @default.
• W2167325977 hasAuthorship W2167325977A5055045706 @default.
• W2167325977 hasAuthorship W2167325977A5085419504 @default.
• W2167325977 hasAuthorship W2167325977A5088307376 @default.
• W2167325977 hasAuthorship W2167325977A5090435894 @default.
• W2167325977 hasBestOaLocation W21673259772 @default.
• W2167325977 hasConcept C10515644 @default.
• W2167325977 hasConcept C121608353 @default.
• W2167325977 hasConcept C126322002 @default.
• W2167325977 hasConcept C143998085 @default.
• W2167325977 hasConcept C144301174 @default.
• W2167325977 hasConcept C2777413986 @default.
• W2167325977 hasConcept C2777583451 @default.
• W2167325977 hasConcept C2778729363 @default.
• W2167325977 hasConcept C2778820342 @default.
• W2167325977 hasConcept C2779536868 @default.
• W2167325977 hasConcept C2908647359 @default.
• W2167325977 hasConcept C3019892230 @default.
• W2167325977 hasConcept C38180746 @default.
• W2167325977 hasConcept C535046627 @default.
• W2167325977 hasConcept C71924100 @default.
• W2167325977 hasConcept C99454951 @default.
• W2167325977 hasConceptScore W2167325977C10515644 @default.
• W2167325977 hasConceptScore W2167325977C121608353 @default.
• W2167325977 hasConceptScore W2167325977C126322002 @default.

• next